SKIN FIBROSIS TREATMENT MARKET ANALYSIS

Skin fibrosis disease is a critical clinical condition resulting in serious disability and badly affecting morbidity, which mostly occurs in skin-restricted and systemic disorders, including localized scleroderma, systemic sclerosis (SSc) and chronic graft-versus-host disease. Fibrosis frequently develops as a result of epidermal or dermal damage brought on by repeated chemical exposure or trauma. It frequently goes hand in hand with chronic inflammation and is defined by an increase in fibrous connective tissues in the dermis or subcutis.

The global skin fibrosis treatment market is estimated to be valued at US$ 609.6 million in 2022 and is expected to exhibit a CAGR of 6.9% during the forecast period (2022-2030).

Figure 1. Global Skin Fibrosis Treatment Market Share (%), by Distribution Channel, 2022

To learn more about this report, request sample copy

Growing prevalence of systemic sclerosis which account one of the main cause for skin fibrosis among the population is expected to drive the global skin fibrosis treatment market.

The increasing prevalence of systemic sclerosis is expected to drive the market growth over the forecast period. For instance, in February 2021, according to data published by the BioMed Central Ltd, part of Springer Nature, prevalence of systemic sclerosis in Italy found out to be 22.2 per 100,000, with the highest prevalence observed for the cases aged ≥ 65 years. In females, SSc was predominant (86.7% on the total) with an overall sex ratio Female/Male of 6.5. Nevertheless, males presented a more severe disease, with a lower survival and notable differences in respiratory complications and metabolic comorbidities. According to the Center for Disease Control and Prevention, prevalence of systemic sclerosis in Europe and North America in 2019 was found to be 13.5-44.3 and 7.2-33.9 per 100,000 individuals.

Figure 2.Global Skin Fibrosis Treatment Market Value (US$ Million), by Region, 2022

To learn more about this report, request sample copy

Rise in research & development activities for the development of skin fibrosis drugs are expected to drive the market growth during the forecast period.

Increasing research and development activities by the key players in the market for the development of skin fibrosis drugs are expected to drive the market growth over the forecast period. For instance, on March 14, 2022, Chemomab Therapeutics, Ltd., a clinical-stage biotechnology company, was focused on development and discovery of ingenious therapeutics for fibrotic and inflammatory diseases with high unmet need. CM-101, was presented with patient sample data and preclinical data as a novel therapy for the treatment of systemic sclerosis.

Global Skin Fibrosis Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global skin fibrosis treatment market, owing to the decrease in research and development activities for the treatment of the skin fibrosis. For instance, in December 2020, according to the data published by the National Center for Biotechnology Information, the research and development activities for the development of vaccines for prevention of coronavirus was on priority. The clinicians and the medical physicians were engaged in the clinical trials and Food and Drug Administration approval for the vaccines used in immunization against COVID-19. The research and development activities for the development of skin fibrosis drugs was slowdown as the impact and response of the Covid-19. The government of different countries imposed lockdown which restricted the availability of the required biological molecules for development of the skin fibrosis treatment drugs.

Global Skin Fibrosis Treatment Market: Key Developments

In May 2022, Michigan Medicine, University of Michigan Hospital, carried out studies on epigenetic drugs, which has shown promising results in cancer treatment significantly in reducing scarring in the cells of patients with scleroderma. The studies revealed that drugs that inhibit Bromodomain-containing protein 4(BRD4) can be used to treat fibrosis in scleroderma. The tests carried out by the researchers for the BRD4 inhibitors on the skin fibroblasts of scleroderma patients and in mice models of skin fibrosis showed that treatment terminated scarring in both animals and in human-derived cells.

Global Skin Fibrosis Treatment Market: Restraint

The major factors that hinder growth of the global skin fibrosis treatment market include high cost of the skin fibrosis drugs. For instance, in April 2017, according to the data published by the Vertex Pharmaceuticals, Biotech Company, include Orkambi (ivacaftor/lumacaftor), Trikafta (ivacaftor/tezacaftor/elexacaftor), carry high list prices between US$ 270,000 and US$ 310,000 per year. The patients with skin fibrosis needs treatment for life time which becomes difficult for people with low income to continue with the skin fibrosis treatment therapy.

Key Players

Major players operating in the global skin fibrosis treatment market include Pharmaxis, Jubilant Cadista, Horizon Pharma USA, Pfizer, Sanofi, F. Hoffmann-La Roche, Boehringer Ingelheim, Bristol-Myers Squibb Company